Results 201 to 210 of about 18,962 (231)
Some of the next articles are maybe not open access.
Nature Reviews Drug Discovery, 2010
In January 2010, liraglutide (Victoza; Novo Nordisk)--an injectable glucagon-like peptide 1 receptor agonist--was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.
Daniel J, Drucker +2 more
openaire +2 more sources
In January 2010, liraglutide (Victoza; Novo Nordisk)--an injectable glucagon-like peptide 1 receptor agonist--was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.
Daniel J, Drucker +2 more
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2011
Liraglutide is the first once-daily human GLP-1 analogue developed for the treatment of type 2 diabetes mellitus(T2DM). The half-life of liraglutide is 13 h following subcutaneous injection, making it suitable for once-daily dosing. Clinical data indicates improved beta cell function with liraglutide treatment in patients with T2DM.
Tomono, Takahashi, Masato, Odawara
openaire +1 more source
Liraglutide is the first once-daily human GLP-1 analogue developed for the treatment of type 2 diabetes mellitus(T2DM). The half-life of liraglutide is 13 h following subcutaneous injection, making it suitable for once-daily dosing. Clinical data indicates improved beta cell function with liraglutide treatment in patients with T2DM.
Tomono, Takahashi, Masato, Odawara
openaire +1 more source